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AbstrAct
Basal cell carcinoma (Bcc) is the most common human malignancy. systemic therapy with a sonic hedgehog (sHH) pathway 
inhibitor plays an important role in the treatment of advanced Bcc. Literature on concurrent use of radiation therapy (rt) with 
sHH inhibitors has been minimal and has solely been focused on vismodegib. We present a case report of a patient with recur-
rent basal cell carcinoma involving the high-risk area of the face, who was denied surgery due to comorbidities and difficulty 
in obtaining complete tumor removal without cosmetic or functional impairment. the patient received combined treatment 
of fractionated radiation with concurrent sonidegib and had complete clinical response with no significant toxicities. this is 
the first reported case on the use of concurrent rt with sonidegib for management of recurrent basal cell carcinoma of the 
head and neck.
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Introduction
Basal cell carcinoma (BCC) is the most common 
human malignancy, with an incidence rate of over 
4 million cases annually. Standard surgical excision 
or Mohs micrographic surgery is the most effective 
and efficient means and the primary modality of 
treatment [1]. Primary RT is an option for patients 
with high-risk BCC who are poor surgical candi-
dates and is an important option for cosmetic and 
functional preservation. In advanced BCC, how-
ever, which is defined as metastatic BCC (mBCC, 
a rare scenario for BCC that refers to distant spread 
to another organ or nonregional lymph node or 
skin involvement) and locally advanced (laBCC) 
that are not amenable to curative surgery or RT 
[2], systemic therapy with a hedgehog pathway in-
hibitor should be considered per current guidelines 
from the American Society for Radiation Oncology 
(ASTRO), National Comprehensive Cancer Net-
work (NCCN) and American Academy of Derma-
tology (AAD) guidelines.
The two sonic hedgehog (SHH) pathway inhibi-
tors approved by the U.S. Food and Drug admin-
istration for advanced BCC are vismodegib (Er-
ivedge) and sonidegib (Odomzo). They work as 
cell surface receptor smoothened homolog (SMO) 
inhibitors, blocking activation of the hedgehog 
pathway [3]. Vismodegib has been used success-
fully and reported in several series of patients with 
advanced or metastatic BCC. Literature reports on 
concurrent use of RT with SMO inhibitors have 
been few and far between, and were mostly focused 
on vismodegib. Current ASTRO guidelines sug-
gest avoiding concurrent use of radiation and SMO 
inhibitors due to the lack of clinical data demon-
strating tolerability. Here, we report the first case 
of concurrent RT with sonidegib in a patient with 
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recurrent BCC of the head and neck who was not 
a surgical candidate.
case presentation
The patient was an 85-year-old male with past 
medical history of coronary artery disease, myo-
cardial infarction, stent placement and bypass graft 
surgery, hypertension, type 2 diabetes mellitus, and 
multiple non-melanoma cutaneous skin cancers 
elsewhere on the head and neck treated with local 
ablation/excision only by dermatology. He was re-
ferred to radiation oncology clinic for stage II BCC 
of left nasal tip s/p surgical resection and sonidegib.
His story began with a nasal tip skin lesion, for 
which he was followed by a dermatologist. Outside 
biopsy on 4/23/18 showed basal cell carcinoma, 
nodular type. It was treated several times by the 
dermatologist before he was referred to otolaryn-
gology. He was seen by otolaryngology and noted 
to have a 3cm lesion involving the left alar rim, 
nasal tip, and left nasal sidewall (Fig. 1A). Maxil-
lofacial computed tomography (CT) scan showed 
a 1.6 cm lesion in the left side of the nose with sur-
rounding skin thickening. There was underlying 
thinning of the left nasal bone, indeterminate for 
nasal bony invasion. Staging workup was consistent 
with T2N0M0, stage II, BCC. Given his cardiac and 
renal conditions and extensive disease prohibitive 
of surgical resection without cosmetic deformity, 
he was deemed unsuitable for surgery and referred 
to medical oncology.
He was seen by medical oncology and was start-
ed on sonidegib (200 mg daily). He had an excellent 
initial response with 85–90% reduction in size clin-
ically (Fig. 1B) and minimal side effects except for 
fatigue. Restaging imaging showed improved, but 
persistent residual disease. After being on sonidegib 
for 3 months, he was referred to Radiation Oncol-
ogy for evaluation. Given the risk of developing 
resistance to SHH inhibitor sonidegib and need to 
treat his disease definitively, RT was recommended 
and patient agreed to proceed.
Patient received intensity-modulated radiation 
therapy with 70 Gy in 35 fractions with concur-
rent sonidegib. A 1 cm CTV margin and a 0.3 mm 
PTV margin were used. A thermoplastic mask was 
used for immobilization. Images from his first day 
and last day of radiation treatment are displayed 
in Figures 1B and 1C, respectively. He tolerated 
the treatment well and side effects were limited to 
fatigue, crusting inside his nasal passage, and ery-
thema of his nasal skin managed with symptomatic 
treatment. On 1-month follow-up, patient reported 
resolving acute symptoms. He was noted to have 
a good response clinically on exam (Figure 1D). On 
7-month follow-up, patient had finished sonidegib 
four months prior (total duration of 8 months) and 
had no residual disease clinically (Fig. 1E). Repeat 
CT imaging showed decreased thickening of soft 
tissue over the left nasal cartilage consistent with 
scar tissue without any focal lesion. The patient’s CT 
imaging over time is displayed in Figure 2. 
Discussion
Sonidegib has only been used as a single agent in 
advanced BCC. It was approved by FDA based on 
the phase II, multicenter, randomized and double-
blinded BOLT clinical trial [4]. It evaluated two 
doses of sonidegib (800 mg or 200 mg daily) in 
patients with laBCC or mBCC until disease pro-
gression or unacceptable toxicity. The study dem-
onstrated a clear role of SMO inhibitors in the 
treatment of advanced BCC, with higher objective 
response (36% vs. 34%), lower adverse events, lon-
ger duration of treatment, a lower discontinuation 
rate and a more favorable benefit-to-risk profile in 
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Figure 1. clinical images at: A. Diagnosis; b. Initiation of radiotherapy (rt); c. Last day of rt; D. one month after rt; E. seven 
month after rt
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200mg dose compared to 800mg dose group. The 
most recent 42-month follow-up of BOLT study 
showed similar results and good safety and long-
term efficacy [5]. Our patient, is the first reported 
case of the use of sonidegib concurrently with RT. 
The patient had excellent clinical response (Fig. 1D 
and 1E) with minimal acute side effects.
There are several hypotheses on possible mecha-
nisms of action for combination therapy with ra-
diation and SHH inhibitors. Ionizing radiation 
works by causing direct and indirect damage to 
cellular DNA and the sonic hedgehog pathway has 
been found to be responsible for resistance to ra-
diotherapy and chemotherapy and recurrence in 
multiple types of cancers [6]. Therefore, combin-
ing radiotherapy and a sonic hedgehog inhibitor 
makes sense theoretically. Molecular and animal 
studies so far indicate that X-rays induce expres-
sion of selected SHH target genes, and that SHH 
signaling is involved in the maintenance of cancer 
stem cells, which are inherently resistant to radia-
tion and some chemotherapies [7, 8]. Gu et al. also 
demonstrated that the combination of focal radia-
tion with SHH inhibitor has ‘more than additive’ 
inhibition of tumor metastasis as shown in an or-
thotopic mouse model for pancreatic cancer. There 
was also increased sensitivity to radiation in both 
the aforementioned mouse model and in basal cell 
carcinoma and head and neck squamous cell carci-
noma cell lines [8, 9].
Vismodegib has been used previously concur-
rently with RT, albeit in small clinical series. Pol-
lom et al. reported 2 cases of recurrent advanced 
BCC treated with concurrent RT and vismodegib 
with good efficacy and tolerance, and no evidence 
of progressive disease at follow-up [10]. Another 
case reported by Raleigh et al. on auricular laBCC 
treated with induction vismodegib and radiation 
showed durable local control and acceptable lev-
el of acute toxicity [11]. Schulze et al. reported 4 
cases (3 recurrent BCC, 1 with locoregional lymph 
node involvement) treated with concurrent vismo-
degib and RT. Three of the 4 patients experienced 
a persistent complete response, whereas one case 
remained stable for 6 months before further tumor 
progression [12]. 
There are no trials directly comparing sonidegib 
with vismodegib. Existing studies attempted to in-
directly compare the BOLT (sonidegib) and ERIV-
ANCE (vismodegib) trials using statistical adjust-
ments. Odom et al. found that in laBCC, sonidegib 
has a higher objective response rate (ORR), longer 
median progression-free survival, and longer me-
dian duration of response [13]. Similarly, Dummer 
et al. found higher ORR for sonidegib, yet same 
efficacy and tolerability profile of the two drugs 
[14]. In mBCC however, sonidegib has a lower ORR 
compared to vismodegib [15]. In terms of their 
cost, the two drugs have comparable average whole-
sale price and cost per year, with sonidegib being 
slightly more affordable [16].
conclusion
Our case report, to our knowledge, is the first re-
ported case of concurrent use of RT and sonidegib 
Figure 2. computed tomography (ct) images from: A. 7-month follow-up visit; b. Before radiotherapy initiation after being 
on sonidegib for 3 month; c. at the time of initial diagnosis. From right to left, resolution of original focal lesion can be 
clearly seen, as well as decreased thickening of the soft tissue over left nasal cartilage and minimal increased density  
of subcutaneous fat
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in recurrent BCC. The patient had excellent clinical 
response with minimal acute side effects. Combi-
nation therapy of SHH inhibitors so far has only 
been limited to case reports, with no phase II trials 
reported. We have explored possible mechanisms 
regarding the synergistic efficacy of RT and SHH 
inhibitors as well as SHH inhibitors’ potential for 
radiosensitization. Future directions include poten-
tial synergistic toxic effects and impaired wound 
healing due to SHH inhibitors [10]. Our report 
shows that concurrent sonidegib and RT is feasible 
and additional prospective study is needed to deter-
mine the optimal path to safely and effectively treat 
patients with laBCC.
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